NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01040026 2023-04-04
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
University Hospital, Basel, Switzerland
Phase 1/2 Completed
NCT03443635 2022-04-29
CHOP
Tulane University
Phase 1/2 Completed
NCT01671488 2020-02-17
276
Brown University
Phase 1/2 Terminated
NCT01892293 2019-01-10
CT Antigen TCR-Engineered T Cells for Myeloma
Adaptimmune
Phase 1/2 Terminated